Skip to main content
HONZ PHARMACEUTICAL CO., LTD. logo

HONZ PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 300086 ISIN · CNE100000QM6 LEI · 300300SA7ZULJ816T861 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 2,012 across all filing types
Latest filing 2022-02-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300086

About HONZ PHARMACEUTICAL CO., LTD.

https://www.honz.com.cn

HONZ Pharmaceutical Co., Ltd. focuses on the research, development, manufacturing, and marketing of pharmaceutical products, with a specialized emphasis on pediatric healthcare. The company provides a diverse range of medications specifically formulated for children, including antipyretics, analgesics, respiratory treatments, and anti-infective agents. It utilizes advanced drug delivery systems and taste-masking technologies to enhance patient compliance and therapeutic efficacy. In addition to its pediatric portfolio, the organization produces various chemical drugs and traditional Chinese medicine preparations. The company maintains multiple production bases and research centers dedicated to advancing clinical solutions and ensuring high standards of product quality across its therapeutic categories.

Recent filings

Filing Released Lang Actions
关于控股股东部分股份质押的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the pledge of shares by the controlling shareholder of the company. It details the number of shares pledged, the proportion of shares pledged relative to total holdings and company capital, the purpose of the pledge, and assurances about the impact on company operations and governance. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory announcement about a shareholder's share pledge, which fits the category of Regulatory Filings (RNS) as it does not fall under more specific categories like Capital/Financing Update (CAP) because it is about share pledge disclosure rather than new financing or capital structure changes. The document length is short and it is a formal disclosure notice, not a full report or presentation.
2022-02-14 Chinese
总裁工作细则
Governance Information Classification · 95% confidence The document is titled as '总裁工作细则' which translates to 'President Work Rules' or 'President Operating Procedures' of 康芝药业股份有限公司 (Kangzhi Pharmaceutical Co., Ltd.). It details the roles, responsibilities, appointment, and operational procedures of the company's president and senior management. It references company laws, securities laws, and the company's articles of association. There is no financial data, no audit information, no earnings or capital updates, no voting results, no legal proceedings, no merger or acquisition information, and no regulatory filings or announcements. The document is a governance-related internal policy document about management roles and procedures. Therefore, it fits best under Governance Information (CGR). The document length is 4791 characters, which is sufficient for a detailed governance report, not a brief announcement or certification. Hence, the classification is CGR with high confidence.
2022-01-25 Chinese
关于公司投资建设民族药制剂楼的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 康芝药业股份有限公司 regarding an investment project to build a new pharmaceutical production facility. It details the investment overview, project description, financial estimates, risk factors, approvals, and independent director opinions. The content focuses on the company's strategic investment decision and project specifics rather than financial results or regulatory filings. It is not a financial report like an Annual Report (10-K) or Interim Report (IR), nor is it a call transcript or audit report. It is also not a report publication announcement or a certification. The document is a formal announcement of a capital investment project, including financing details and project approval, which fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive information about the investment and financing plan, not just a brief notice or summary. Therefore, the most appropriate classification is CAP with high confidence.
2022-01-25 Chinese
信息披露管理制度
Governance Information Classification · 95% confidence The document is titled '信息披露管理制度' which translates to 'Information Disclosure Management System' and contains detailed internal rules and procedures for information disclosure by the company 康芝药业股份有限公司. It references regulatory frameworks such as the Securities Law of China, Shenzhen Stock Exchange rules, and outlines responsibilities of the board, management, and disclosure processes. It does not contain financial statements, audit results, or earnings data, nor is it an announcement or transcript. It is a governance document detailing internal rules and governance practices related to information disclosure. Therefore, it fits the category of Governance Information (CGR). The document length and content confirm it is a full policy document, not a brief announcement or report publication notice.
2022-01-25 Chinese
披露暂缓与豁免事务管理制度
Governance Information Classification · 100% confidence The document is a detailed internal policy titled 'Information Disclosure Delay and Exemption Management System' for a company, 康芝药业股份有限公司. It outlines procedures, conditions, responsibilities, and internal approval processes related to delaying or exempting information disclosure. It includes definitions, internal management procedures, responsibilities, and attachments such as approval forms and confidentiality commitment letters. There is no financial data, no report of financial results, no earnings announcement, no voting results, no legal proceedings, no capital changes, no management changes, no audit opinions, no call transcripts, no presentations, and no regulatory filings or announcements. The document is a governance-related internal policy document about disclosure practices and compliance with securities laws and stock exchange rules. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-01-25 Chinese
投资者关系管理制度
Governance Information Classification · 95% confidence The document is titled as an "Investor Relations Management System" for 康芝药业股份有限公司, detailing the company's policies, principles, organizational structure, and procedures for managing investor relations. It includes sections on communication with investors, disclosure principles, interaction methods, and responsibilities of company personnel. There are no financial statements, earnings data, or regulatory filings such as annual or quarterly reports. The document is a governance-related policy document focused on investor relations management rather than a report or announcement of financial results or corporate actions. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2022-01-25 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.